Physician profile
Jacadi Bignami
NPI 1780023804
$2,364.26
in general payments reported to CMS, 2019-2025
16 companies · $32.28 in 2025
The $32.28 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $487 · 2020: $377 · 2021: $492 · 2022: $550 · 2023: $350 · 2024: $76.41 · 2025: $32.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $458.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.45 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Organon LLC | $317.53 | 2022-2023 | Nexplanon |
| Therapeuticsmd, INC. | $251.83 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $112.40 | 2023-2024 | Myfembree |
| Exeltis, USA INC. | $103.86 | 2023 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $83.42 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $82.64 | 2021-2023 | |
| Hologic Sales and Service, LLC | $67.55 | 2019-2025 | Aptima |
| Merck Sharp & Dohme LLC | $64.43 | 2019-2021 | |
| Pfizer INC. | $60.74 | 2021-2024 | |
| Astellas Pharma US INC | $60.39 | 2023-2024 | Veozah |
| Allergan, INC. | $55.92 | 2019 | |
| Myovant Sciences INC. | $55.19 | 2022 | |
| Amag Pharmaceuticals, INC. | $42.80 | 2019-2020 | |
| Lupin INC. | $30.37 | 2019-2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacadi Bignami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.